Clinical Trials Directory

Trials / Completed

CompletedNCT04315116

A Drug-drug Interaction Trial of Loperamide Pharmacokinetics Effect on Pyrotinib Maleate

A Single Center, Single Arm, Open and Fixed Sequence Study to Investigate the Pharmacokinetic Effects of Loperamide on Pyrotinib Maleate in Healthy Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
18 (actual)
Sponsor
Jiangsu HengRui Medicine Co., Ltd. · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The primary objective of the study was to assess the effect of repeated oral doses of Loperamide on the pharmacokinetic profile of a single dose of Pyrotinib Maleate. The secondary objective of the study was to assess the safety of Pyrotinib Maleate given alone versus Fluzoparib coadministered with Loperamide.

Conditions

Interventions

TypeNameDescription
DRUGpyrotinib maleatea single oral dose of pyrotinib maleate on day 1 \& day10 .
DRUGLoperamideLoperamide 4 mg bid from day 7 to day 13

Timeline

Start date
2020-04-13
Primary completion
2020-04-30
Completion
2020-09-01
First posted
2020-03-19
Last updated
2022-10-28

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04315116. Inclusion in this directory is not an endorsement.

A Drug-drug Interaction Trial of Loperamide Pharmacokinetics Effect on Pyrotinib Maleate (NCT04315116) · Clinical Trials Directory